<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimberly A Yonkers, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert F Casper, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The premenstrual syndrome (PMS) and the more severe variant of premenstrual dysphoric disorder (PMDD), also called late luteal phase dysphoric disorder in previous versions of the Diagnostic and Statistical Manual (DSM), are characterized by the presence of physical and/or behavioral symptoms that occur repetitively in the second half of the menstrual cycle and often the first few days of menses. The severity of PMS or PMDD symptoms lead to interference with some aspects of the female's life, including social relations, work in or outside the home, etc. The most common physical manifestation is abdominal bloating [<a href="#rid1">1,2</a>]. Breast tenderness and headaches are also common  (<a class="graphic graphic_table graphicRef86227" href="/d/graphic/86227.html" rel="external">table 1</a>). The emotional symptoms lead to greater impairment than do physical symptoms [<a href="#rid3">3</a>].</p><p>The diagnosis of PMDD is discussed in greater detail elsewhere. The clinical manifestations, diagnosis, and treatment of PMS/PMDD are discussed separately. (See  <a class="medical medical_review" href="/d/html/7381.html" rel="external">"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder"</a> and  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Premenstrual dysphoric disorder (PMDD), as defined by the American Psychiatric Association (APA) Diagnostic and Statistical Manual, Fifth Edition (DSM-5), can be differentiated from premenstrual syndrome (PMS) by the presence of at least five symptoms, including one affective symptom, such as mood swings, irritability, and/or depression [<a href="#rid4">4</a>].</p><p>The prevalence of PMS and PMDD in the population have been overestimated because of the failure to apply strict diagnostic criteria (see  <a class="medical medical_review" href="/d/html/7381.html" rel="external">"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Diagnostic criteria'</a>). Estimates as high as 80 percent have been reported for PMS, based upon the inclusion of females who have any form of premenstrual mood or physical symptoms [<a href="#rid5">5</a>]. When one applies strict inclusion criteria, estimates for PMS are around 20 to 30 percent and 2 percent for PMDD, as illustrated by three community studies that used prospective ratings to determine the diagnosis [<a href="#rid6">6-9</a>]. (See  <a class="medical medical_review" href="/d/html/7381.html" rel="external">"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Evaluation'</a>.)</p><p>PMS is described in diverse cultural settings, even among females who are not generally aware of the disorder. As an example, similar rates of the disorder are reported in Mediterranean countries, the Middle East, Iceland, Kenya, New Zealand, and Asia [<a href="#rid10">10-13</a>]. The point prevalence of retrospectively reported symptoms range from 2.8 to 6.4 percent [<a href="#rid14">14,15</a>]. In an international survey of 7226 females in Europe, South America, and Asia, the frequency of PMS symptoms is similar across countries and regions, but females in some countries, such as Pakistan, are less familiar with the term PMS when compared with European females [<a href="#rid16">16</a>]. Symptoms that are most commonly reported are abdominal bloating, cramps, irritability, mastalgia, and joint and back pains.</p><p>In the United States, Black females were less likely to experience PMDD than White females. The prevalence of PMDD was 2.9 percent among Black females versus 4.4 percent among White females [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H255917"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The role of genetic factors in the predisposition to premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) is an area of active exploration, although definitive findings are not yet available. It does not appear that females with and without PMDD inherit different alleles of the serotonin transporter. Some studies suggest a possible association with the estrogen receptor alpha (<em>ESR1</em>) gene [<a href="#rid18">18-20</a>]. In one report, cells from females with and without PMDD showed different response patterns to components of the ESC/E(Z) (Extra Sex Combs/Enhancer of Zeste) complex that includes the ESR1 gene [<a href="#rid21">21</a>].</p><p>Other possible risk factors for the development of PMDD include lower education and cigarette smoking [<a href="#rid22">22</a>], a history of traumatic events or anxiety disorder, and higher "daily hassle scores" [<a href="#rid23">23</a>], although these are risk factors for a number of mood and anxiety disorders.</p><p class="headingAnchor" id="H255765"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The available evidence suggests that premenstrual syndrome (PMS) is a disorder triggered by changes in gonadal steroids during the luteal phase in susceptible females. This is thought to result from the interaction between cyclic changes in ovarian steroids and the functioning of central neurotransmitters. The neurotransmitter that is most implicated in the manifestations of PMS is serotonin, although there is evidence to implicate beta-endorphin, gamma-aminobutyric acid (GABA), and the autonomic nervous system.</p><p>In addition, some of the systemic manifestations, such as the feeling of bloating, may be produced by peripheral mechanisms. There may also be a role for calcium dysregulation in the pathogenesis of PMS [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Ovarian steroids</span><span class="headingEndMark"> — </span>A central role for ovarian steroids in the etiology of PMS is strongly supported by a series of experiments in which "medical ovariectomy" using a gonadotropin-releasing hormone (GnRH) agonist led to dramatic resolution of PMS symptoms [<a href="#rid5">5,25,26</a>]. However, cyclic changes in ovarian steroids do <strong>not</strong> appear to be the sole cause of PMS symptoms, as daily serum estrogen and progesterone concentrations are similar in females with PMS/premenstrual dysphoric disorder (PMDD) and controls [<a href="#rid27">27,28</a>].</p><p>Deficiencies in progesterone, progesterone metabolites (some of which have anxiolytic properties), and the progesterone receptor have also been proposed as possible mediators of PMS/PMDD. However, as noted, serum progesterone concentrations are normal in females with PMS. In addition, serum concentrations of the progesterone metabolites, allopregnanolone and pregnenolone, are similar in females with PMS compared with normal females [<a href="#rid29">29</a>]. Lastly, blocking the effect of progesterone in the luteal phase with a progesterone receptor antagonist (<a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>) does not alleviate the symptoms of PMS [<a href="#rid30">30</a>]. It is possible that females with PMS/PMDD may have more sensitive downregulation of central estrogen receptors in response to normal levels of progesterone. This possibility is suggested by the documentation of hot flushes, identical physiologically to menopausal hot flushes, during the late luteal phase in females with clinically severe PMS [<a href="#rid31">31</a>].</p><p>Although females with PMS have normal concentrations of serum estrogen and progesterone, they may have an <strong>abnormal response</strong> to normal hormonal changes. In a double-blind, crossover trial of females with PMS, for example, 10 females who received <a class="drug drug_general" data-topicid="9549" href="/d/drug information/9549.html" rel="external">leuprolide</a> had a significant decrease in symptoms compared with females who received placebo [<a href="#rid25">25</a>]. However, subsequent administration of either estrogen or progesterone in addition to leuprolide resulted in a significant recurrence of symptoms. In contrast, no changes in mood occurred in 15 control females without PMS who received the same regimen, or in five females with PMS who were given leuprolide plus placebo postmenopausal hormone therapy. These findings suggest that gonadal steroids are necessary, but not sufficient, to cause symptoms of PMS. The biological basis for these findings are related to a 2014 paper exploring genetic pathways for risk. (See <a class="local">'Risk factors'</a> above.)</p><p class="headingAnchor" id="H5"><span class="h2">Neurotransmitters</span><span class="headingEndMark"> — </span>Based upon in vitro data and animal studies, there is evidence that cyclic fluctuations in circulating estrogen and progesterone cause marked changes in the opioid [<a href="#rid32">32</a>], GABA [<a href="#rid33">33</a>], and serotonin [<a href="#rid34">34</a>] systems. At one time, it was thought that the symptom constellation of PMS resulted from steroid-induced changes in the opioid system. Differences in peripheral beta-endorphin levels are observed in females with PMS compared with controls in the periovulatory and premenstrual phases of the cycle [<a href="#rid35">35-37</a>]. However, attempts to confirm these peripheral findings with provocative tests to probe central opiate activity have not been successful [<a href="#rid38">38</a>].</p><p>The potential role of the GABAergic system in PMS has not been extensively investigated. However, in vitro data suggesting this system is modulated by progestin are corroborated indirectly by the observation that the benzodiazepine <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> is effective in treating PMS symptoms [<a href="#rid39">39</a>] (see  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Other therapies'</a>). In addition, low levels of the progesterone metabolite allopregnanolone, which enhances GABA-A receptor function and possesses anxiolytic effects, is thought to have a mechanistic role [<a href="#rid40">40</a>]. Clinical trial data finding that an antagonist to allopregnanolone, administered prior to the rise in luteal phase progesterone and allopregnanolone levels, blunts symptoms to a greater extent than does placebo [<a href="#rid41">41</a>]. Data on whether serum allopregnanolone concentrations differ between symptomatic and asymptomatic females conflict, but peripheral levels may not reflect central levels nor does it speak to receptor activity [<a href="#rid29">29,40</a>].</p><p>Evidence continues to support a role for serotonin in the etiology of PMS. This can be illustrated by the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with PMS, when compared with controls, have lower whole blood serotonin and platelet serotonin uptake and <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a> binding during the luteal phase of the menstrual cycle [<a href="#rid42">42-46</a>], and higher cerebrospinal fluid levels of the serotonin metabolite 5-hydroxyindoleacetic acid as compared with the dopamine metabolite homovanillic acid [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The symptoms of PMS are ameliorated by the serotonin agonist <a class="drug drug_general" data-topicid="128557" href="/d/drug information/128557.html" rel="external">fenfluramine</a> [<a href="#rid48">48</a>] and aggravated by acute depletion of the serotonin precursor tryptophan [<a href="#rid49">49</a>]. In addition, serotonin reuptake inhibitors, such as <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, are one of the most effective drugs for the treatment of PMS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of metergoline, a serotonin antagonist, to fluoxetine-treated females with PMDD causes a return of mood symptoms [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serotonin reuptake inhibitors may influence the metabolic pathway of progesterone and allopregnanolone production [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Role of vitamins and minerals</span><span class="headingEndMark"> — </span>Attempts to detect vitamin deficiency in females with PMS have been unsuccessful, and vitamin therapies are not considered to be an effective therapy.</p><p>No differences in vitamin E, vitamin A, or <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">vitamin B6</a> levels are found [<a href="#rid52">52,53</a>]. However, in one cohort study, females with high intakes of the B vitamins thiamine and riboflavin from food sources were less likely to develop PMS than those who had low intakes [<a href="#rid54">54</a>]. No significant associations were seen between PMS and dietary intake of other B vitamins. Intake of B vitamins from supplements was not associated with a lower risk of PMS. Several vitamins and dietary supplements, including vitamin B6, vitamin E, vitex agnus castus, calcium, and magnesium, were studied as therapeutic agents for PMS; however, evidence that any of these, with the exception of vitex agnus castus, is more effective than placebo is inconsistent. (See  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Other'</a>.)</p><p>Several reports suggest that patients with PMS may have lower levels of intracellular magnesium over the course of the menstrual cycle [<a href="#rid55">55,56</a>], although studies of altered serum levels have produced inconsistent results [<a href="#rid57">57-59</a>]. One well-conducted study showed an improvement in total PMS symptom scores and affective symptoms with the administration of magnesium pyrrolidone carboxylic acid (360 mg three times daily in the second half of the menstrual cycle) [<a href="#rid60">60</a>]. However, in other studies, magnesium was ineffective. (See  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Other'</a>.)</p><p class="headingAnchor" id="H2403946547"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117520.html" rel="external">"Society guideline links: Diagnosis and treatment of premenstrual dysphoric disorder"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16161.html" rel="external">"Patient education: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2159.html" rel="external">"Patient education: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H151092800"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions – </strong>The premenstrual syndrome (PMS) is characterized by the presence of <strong>both</strong> physical and behavioral symptoms that occur repetitively in the second half of the menstrual cycle and interfere with some aspects of the female's life. Premenstrual dysphoric disorder (PMDD) is a severe form of PMS in which symptoms of anger, irritability, and internal tension are prominent. (See  <a class="medical medical_review" href="/d/html/7381.html" rel="external">"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>-<strong> </strong>Clinically significant PMS affects 20 to 30 percent of females with regular menstrual cycles, while true PMDD affects only approximately 2 percent of females in this group. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>-<strong> </strong>Both genetic and environmental factors play a role in the development of premenstrual symptoms. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preliminary evidence suggests that risk for PMDD is associated with genetic variation in <em>ESR1</em>, the estrogen receptor alpha gene. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other possible risk factors for the development of PMDD include lower education, cigarette smoking, and a history of traumatic events or anxiety disorder. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the normal menstrual cycle, cyclic fluctuations in luteal phase estrogen and progesterone concentrations cause marked changes in neurotransmitters, most notably, the serotonin system. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Females with PMS/PMDD have normal concentrations of serum estrogen and progesterone, but they appear to have an <strong>abnormal neurotransmitter response</strong> (in particular, serotonin) to luteal phase hormonal changes. (See <a class="local">'Neurotransmitters'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among the neurotransmitters, serotonin appears to play the most important role in the etiology of PMS/PMDD, as illustrated by the following observations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Selective serotonin reuptake inhibitors (SSRIs) are the most effective therapy for the disorder. (See  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Other'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When females with PMDD who are symptom-free on SSRI therapy are subsequently treated with a serotonin antagonist, they experience a return in their mood symptoms. (See <a class="local">'Neurotransmitters'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Limited data suggest that high intake of <a class="drug drug_general" data-topicid="9839" href="/d/drug information/9839.html" rel="external">vitamin B6</a> (from the diet, but not from supplements) is associated with a lower risk of PMS/PMDD. A number of vitamins and dietary supplements, including vitamin B6, vitamin E, vitex agnus castus, calcium, and magnesium, have been studied as therapeutic agents for PMS; however, evidence that any of these is more effective than placebo, which has a 30 percent response rate, is inconsistent. (See <a class="local">'Role of vitamins and minerals'</a> above and  <a class="medical medical_review" href="/d/html/7382.html" rel="external">"Treatment of premenstrual syndrome and premenstrual dysphoric disorder", section on 'Other'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8:122.</a></li><li><a class="nounderline abstract_t">Hartlage SA, Freels S, Gotman N, Yonkers K. Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets. Arch Gen Psychiatry 2012; 69:300.</a></li><li><a class="nounderline abstract_t">Schmalenberger KM, Eisenlohr-Moul TA, Surana P, et al. Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis. Psychol Med 2017; 47:1585.</a></li><li><a class="nounderline abstract_t">Epperson CN, Steiner M, Hartlage SA, et al. Premenstrual dysphoric disorder: evidence for a new category for DSM-5. Am J Psychiatry 2012; 169:465.</a></li><li><a class="nounderline abstract_t">Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101:689.</a></li><li><a class="nounderline abstract_t">Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147:1634.</a></li><li><a class="nounderline abstract_t">Soares CN, Cohen LS, Otto MW, Harlow BL. Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles. J Womens Health Gend Based Med 2001; 10:873.</a></li><li><a class="nounderline abstract_t">Gehlert S, Song IH, Chang CH, Hartlage SA. The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med 2009; 39:129.</a></li><li><a class="nounderline abstract_t">Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007; 109:1068.</a></li><li><a class="nounderline abstract_t">Raja SN, Feehan M, Stanton WR, McGee R. Prevalence and correlates of the premenstrual syndrome in adolescence. J Am Acad Child Adolesc Psychiatry 1992; 31:783.</a></li><li><a class="nounderline abstract_t">Monagle L, Dan A, Krogh V, et al. Perimenstrual symptom prevalence rates: an Italian-American comparison. Am J Epidemiol 1993; 138:1070.</a></li><li><a class="nounderline abstract_t">Rupani NP, Lema VM. Premenstrual tension among nurses in Nairobi, Kenya. East Afr Med J 1993; 70:310.</a></li><li><a class="nounderline abstract_t">Sveinsdóttir H, Marteinsdóttir G. Retrospective assessment of premenstrual changes in Icelandic women. Health Care Women Int 1991; 12:303.</a></li><li><a class="nounderline abstract_t">Dennerstein L, Lehert P, Heinemann K. Epidemiology of premenstrual symptoms and disorders. Menopause Int 2012; 18:48.</a></li><li><a class="nounderline abstract_t">Choi D, Lee DY, Lehert P, et al. The impact of premenstrual symptoms on activities of daily life in Korean women. J Psychosom Obstet Gynaecol 2010; 31:10.</a></li><li><a class="nounderline abstract_t">Dennerstein L, Lehert P, Heinemann K. Global study of women's experiences of premenstrual symptoms and their effects on daily life. Menopause Int 2011; 17:88.</a></li><li><a class="nounderline abstract_t">Pilver CE, Kasl S, Desai R, Levy BR. Health advantage for black women: patterns in pre-menstrual dysphoric disorder. Psychol Med 2011; 41:1741.</a></li><li><a class="nounderline abstract_t">Miller A, Vo H, Huo L, et al. Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls. J Psychiatr Res 2010; 44:788.</a></li><li><a class="nounderline abstract_t">Huo L, Straub RE, Roca C, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 2007; 62:925.</a></li><li><a class="nounderline abstract_t">Pakharenko L. Effect of estrogen receptor gene ESR1 polymorphism on development of premenstrual syndrome. Georgian Med News 2014; :37.</a></li><li><a class="nounderline abstract_t">Dubey N, Hoffman JF, Schuebel K, et al. The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Mol Psychiatry 2017; 22:1172.</a></li><li><a class="nounderline abstract_t">Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles. J Affect Disord 2002; 70:125.</a></li><li><a class="nounderline abstract_t">Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry 2004; 65:1314.</a></li><li><a class="nounderline abstract_t">Thys-Jacobs S, McMahon D, Bilezikian JP. Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder. J Clin Endocrinol Metab 2007; 92:2952.</a></li><li><a class="nounderline abstract_t">Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209.</a></li><li><a class="nounderline abstract_t">Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Am J Psychiatry 2017; 174:980.</a></li><li><a class="nounderline abstract_t">Andersch B, Abrahamsson L, Wendestam C, et al. Hormone profile in premenstrual tension: effects of bromocriptine and diuretics. Clin Endocrinol (Oxf) 1979; 11:657.</a></li><li><a class="nounderline abstract_t">Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand 1979; 60:76.</a></li><li><a class="nounderline abstract_t">Schmidt PJ, Purdy RH, Moore PH Jr, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79:1256.</a></li><li><a class="nounderline abstract_t">Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994; 84:1001.</a></li><li><a class="nounderline abstract_t">Casper RF, Graves GR, Reid RL. Objective measurement of hot flushes associated with the premenstrual syndrome. Fertil Steril 1987; 47:341.</a></li><li><a class="nounderline abstract_t">Wardlaw SL, Thoron L, Frantz AG. Effects of sex steroids on brain beta-endorphin. Brain Res 1982; 245:327.</a></li><li><a class="nounderline abstract_t">Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232:1004.</a></li><li><a class="nounderline abstract_t">Bethea CL. Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology 1994; 60:50.</a></li><li><a class="nounderline abstract_t">Chuong CJ, Coulam CB, Kao PC, et al. Neuropeptide levels in premenstrual syndrome. Fertil Steril 1985; 44:760.</a></li><li><a class="nounderline abstract_t">Chuong CJ, Hsi BP, Gibbons WE. Periovulatory beta-endorphin levels in premenstrual syndrome. Obstet Gynecol 1994; 83:755.</a></li><li><a class="nounderline abstract_t">Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990; 20:279.</a></li><li><a class="nounderline abstract_t">Chuong CJ, Hsi BP. Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome. Fertil Steril 1994; 61:1039.</a></li><li><a class="nounderline abstract_t">Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987; 70:37.</a></li><li><a class="nounderline abstract_t">Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90:709.</a></li><li><a class="nounderline abstract_t">Bäckström T, Ekberg K, Hirschberg AL, et al. A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology 2021; 133:105426.</a></li><li><a class="nounderline abstract_t">Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70:533.</a></li><li><a class="nounderline abstract_t">Taylor DL, Mathew RJ, Ho BT, Weinman ML. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12:16.</a></li><li><a class="nounderline abstract_t">Ashby CR Jr, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24:225.</a></li><li><a class="nounderline abstract_t">Steege JF, Stout AL, Knight DL, Nemeroff CB. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 1992; 167:168.</a></li><li><a class="nounderline abstract_t">Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31:146.</a></li><li><a class="nounderline abstract_t">Eriksson E, Alling C, Andersch B, et al. Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacology 1994; 11:201.</a></li><li><a class="nounderline abstract_t">Brzezinski AA, Wurtman JJ, Wurtman RJ, et al. d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990; 76:296.</a></li><li><a class="nounderline abstract_t">Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32:37.</a></li><li><a class="nounderline abstract_t">Roca CA, Schmidt PJ, Smith MJ, et al. Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. Am J Psychiatry 2002; 159:1876.</a></li><li><a class="nounderline abstract_t">Fry JP, Li KY, Devall AJ, et al. Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase. Br J Pharmacol 2014; 171:5870.</a></li><li><a class="nounderline abstract_t">Chuong CJ, Dawson EB, Smith ER. Vitamin A levels in premenstrual syndrome. Fertil Steril 1990; 54:643.</a></li><li><a class="nounderline abstract_t">Chuong CJ, Dawson EB, Smith ER. Vitamin E levels in premenstrual syndrome. Am J Obstet Gynecol 1990; 163:1591.</a></li><li><a class="nounderline abstract_t">Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr 2011; 93:1080.</a></li><li><a class="nounderline abstract_t">Sherwood RA, Rocks BF, Stewart A, Saxton RS. Magnesium and the premenstrual syndrome. Ann Clin Biochem 1986; 23 ( Pt 6):667.</a></li><li><a class="nounderline abstract_t">Facchinetti F, Borella P, Fioroni L, et al. Reduction of monocyte magnesium in patients affected by premenstrual syndrome. J Psychosom Obstet Gynaecol 1990; 11:221.</a></li><li><a class="nounderline abstract_t">Rosenstein DL, Elin RJ, Hosseini JM, et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry 1994; 35:557.</a></li><li><a class="nounderline abstract_t">Cerin A, Collins A, Landgren BM, Eneroth P. Hormonal and biochemical profiles of premenstrual syndrome. Treatment with essential fatty acids. Acta Obstet Gynecol Scand 1993; 72:337.</a></li><li><a class="nounderline abstract_t">Posaci C, Erten O, Uren A, Acar B. Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome. Acta Obstet Gynecol Scand 1994; 73:452.</a></li><li><a class="nounderline abstract_t">Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991; 78:177.</a></li></ol></div><div id="topicVersionRevision">Topic 7380 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10101982" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Biological, social, and behavioral factors associated with premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393222" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Criteria for premenstrual dysphoric disorder: secondary analyses of relevant data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193300" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22764360" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Premenstrual dysphoric disorder: evidence for a new category for DSM-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947504" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2244641" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Late luteal phase dysphoric disorder in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11747682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Characteristics of women with premenstrual dysphoric disorder (PMDD) who did or did not report history of depression: a preliminary report from the Harvard Study of Moods and Cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366818" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470584" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Using the daily record of severity of problems as a screening instrument for premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1400109" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevalence and correlates of the premenstrual syndrome in adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266909" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Perimenstrual symptom prevalence rates: an Italian-American comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306911" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Premenstrual tension among nurses in Nairobi, Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1885341" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Retrospective assessment of premenstrual changes in Icelandic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22611221" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epidemiology of premenstrual symptoms and disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20146640" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of premenstrual symptoms on activities of daily life in Korean women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903712" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Global study of women's experiences of premenstrual symptoms and their effects on daily life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21108869" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health advantage for black women: patterns in pre-menstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172536" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Estrogen receptor alpha (ESR-1) associations with psychological traits in women with PMDD and controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599809" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416214" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of estrogen receptor gene ESR1 polymorphism on development of premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28044059" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117624" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491233" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488795" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cyclical changes in calcium metabolism across the menstrual cycle in women with premenstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9435325" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427285" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/575318" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hormone profile in premenstrual tension: effects of bromocriptine and diuretics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/573048" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Plasma progesterone, oestradiol 17 beta and premenstrual symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962316" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7970453" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3817175" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Objective measurement of hot flushes associated with the premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6289967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of sex steroids on brain beta-endorphin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2422758" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8090282" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Regulation of progestin receptors in raphe neurons of steroid-treated monkeys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2934273" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Neuropeptide levels in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164939" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Periovulatory beta-endorphin levels in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2265889" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Beta-endorphin decline in late luteal phase dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8194614" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of naloxone on luteinizing hormone secretion in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3299178" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351749" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Progesterone metabolite allopregnanolone in women with premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34597899" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627623" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Whole-blood serotonin in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6542630" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serotonin levels and platelet uptake during premenstrual tension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3390499" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442921" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649111" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7532413" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cerebrospinal fluid levels of monoamine metabolites. A preliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2371034" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7798465" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute tryptophan depletion aggravates premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411222" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of metergoline on symptoms in women with premenstrual dysphoric disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25161074" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2120085" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vitamin A levels in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2122725" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Vitamin E levels in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346091" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dietary B vitamin intake and incident premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800293" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Magnesium and the premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Reduction of monocyte magnesium in patients affected by premenstrual syndrome</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038300" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Magnesium measures across the menstrual cycle in premenstrual syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8392261" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hormonal and biochemical profiles of premenstrual syndrome. Treatment with essential fatty acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8042455" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Plasma copper, zinc and magnesium levels in patients with premenstrual tension syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2067759" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oral magnesium successfully relieves premenstrual mood changes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
